Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.53 |
| ▸ | HTR2C | P28335 | 5/20 | 0.53 |
| ▸ | HTR2B | P41595 | 5/20 | 0.53 |
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | HTR1D | P28221 | 3/20 | 0.53 |
| ▸ | HTR1B | P28222 | 2/20 | 0.53 |
| ▸ | HTR1E | P28566 | 2/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | HTR5A | P47898 | 2/20 | 0.53 |
| ▸ | HTR1F | P30939 | 2/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210376 | 1.00 | HTR2A (0.53) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL4977478 | 0.94 | HTR1A (0.55) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL27084716 | 0.91 | HTR6 (0.52) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL27084689 | 0.90 | HTR2A (0.50) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL27084889 | 0.89 | HTR2A (0.56) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL26186708 | 0.89 | MTNR1A (0.55) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL20970978 | 0.89 | HTR6 (0.54) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL29633057 | 0.89 | HTR6 (0.54) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL25790828 | 0.89 | HTR2A (0.59) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL23069129 | 0.88 | HTR2A (0.51) | HTR2AHTR2CHTR2BHTR1AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20240398750-A1 | Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators. | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240398751-A1 | Methods of treating or reducing symptoms of stimulant dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and glutamate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-12-05 | — | — | US | claimed |
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | US | claimed |
| US-20240325342-A1 | Methods of treating or reducing symptoms of opiate dependency (addiction) via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and opiate allosteric modulators | HELDRETH JR DAVID ALAN (US) | 2024-10-03 | — | — | US | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023028086-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022261263-A1 | METHODS OF TREATING NEUROPSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-12-15 | — | — | WO | claimed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| US-20250375421-A1 | METHODS OF USING DMT | SHULMAN WILLIAM (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | disclosed |
| EP-4061359-A1 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | Turtle Bear Holdings, LLC (US) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022195489-A2 | IMPROVED METHODS FOR THE USE OF PSYCHEDELICS | TRYP THERAPEUTICS INC. (CA) | 2022-09-22 | — | — | WO | disclosed |
| US-20220265601-A1 | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. | Heldreth, JR., David Alan (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220054402-A1 | COMPOSITIONS AND METHODS FOR EXTRACTING, STABILIZING, AND MANUFACTURING STABLE DOSAGE FORMS OF PSILOCIN, PSYCHEDELIC DRUGS, ENTHEOGENS, AND MEDICINAL MUSHROOMS AS NANO-DIMENSIONAL DRUG DELIVERY STRUCTURES | KAUFMAN RICHARD C (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390301-A1 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | HTR2A, HTR2C, HTR5A | HTR2A 1/4885HTR2C 2/4885HTR2B 5/4885 |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | HTR2A 33/4885HTR2C 55/4885HTR2B 87/4885 |
| US-20250375421-A1 | METHODS OF USING DMT | PNMT, HTR6, HTR1A | HTR2A 5/4885HTR2C 14/4885HTR2B 16/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885HTR2C 42/4885HTR2B 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.